share_log

Plus Therapeutics Has Acquired Assets For The Synergistic Leptomeningeal Metastases Diagnostic Platform, Financial Terms Not Disclosed; Topline Clinical Trial Data On The FORESEE Trial, Met Its Primary Endpoint Of Clinical Utility

Benzinga ·  May 9 23:36

CNSide can significantly improve LM diagnostic accuracy and the market size for Plus' lead LM radiotherapeutic candidate rhenium (Re186) obisbemeda

Company summarized topline data from the FORESEE clinical trial planned for complete presentation at the SNO/ASCO Meeting in August 2024

Call replay & transcript available via the link below

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment